US4988515A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cardioplegic solution
Assignee: GERALD BUCKBERG
•
Filing: 1989-04-05
•
Granted: 1991-01-29
•
Expires: 2009-04-05
Abstract
Abstract An improved amino acid enriched cardioplegic solution adapted for use in preventing and treating heart muscle damage due to regional ischemia. The solution includes a calcium ion concentration of between about 50-300 umol, a metabolizable substrate concentration of 400-1000 mg % and an osmolarity of between about 400-500 mOsmols.
Inventors
- 👤 Gerald D. Buckberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:24
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/197; A61K31/194; A61K31/70; A61K31/7004; A61K33/00; A61K33/06; A61K47/00; A61K47/06; A61K47/30; A61K47/42; A61K47/46; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
121 words
In an amino acid enriched cardioplegic solution for use in treating human hearts to prevent or reverse heart muscle damage due to ischemia, said cardioplegic solution having a calcium ion concentration, a metabolizable substrate concentration and an osmolarity, wherein the improvement comprises: maintaining said calcium ion concentration of said cardioplegic solution at a lowered level of between about 50-300 umol; maintaining said concentration of metabolizable substrate in said cardioplegic solution between about 400-1000 mg % wherein said metabolizable substrate is selected from the group consisting of glucose, fructose, a salt of malic acid, a salt of succinic acid and a salt of pyruvic acid; and maintaining said osmolarity of said cardioplegic solution at an increased level of between about 400-500 mOsmol.
Claim 2
Dependent Claim
121 words
In an amino acid enriched cardioplegic solution for use in treating human hearts to prevent or reverse heart muscle damage due to ischemia, said cardioplegic solution having a calcium ion concentration, a metabolizable substrate concentration and an osmolarity, wherein the improvement comprises: maintaining said calcium ion concentration of said cardioplegic solution at a lowered level of between about 50-300 umol; maintaining said concentration of metabolizable substrate in said cardioplegic solution between about 400-1000 mg % wherein said metabolizable substrate is selected from the group consisting of glucose, fructose, a salt of malic acid, a salt of succinic acid and a salt of pyruvic acid; and maintaining said osmolarity of said cardioplegic solution at an increased level of between about 400-500 mOsmol.
Claim 3
Dependent Claim
25 words
An improved cardioplegic solution according to claim 1 wherein said metabolizable substrate is selected from the group consisting of glucose, fructose, malate succinate and pyruvate.
Claim 4
Dependent Claim
28 words
An improved cardioplegic solution according to claim 1 wherein said solution includes a carrier selected from the group consisting of blood, stroma free hemoglobin, oxygenated plasma and fluorocarbons.
Claim 5
Dependent Claim
13 words
An improved cardioplegic solution according to claim 3 wherein said carrier is blood.
Claim 6
Dependent Claim
19 words
An improved cardioplegic solution according to claim 2 wherein said solution includes 10-30 mmol aspartate and 10-30 mmol glutamate.
Claim 7
Dependent Claim
14 words
An improved cardioplegic solution according to claim 5 wherein said metabolizable substrate is glucose.
Claim 8
Dependent Claim
82 words
In a method for treating human hearts with an amino acid enriched cardioplegic solution to prevent or reverse heart muscle damage due to ischemia, said solution having a calcium ion concentration, a metabolizable substrate concentration and an osmolarity, wherein the improvement comprises: maintaining said calcium ion concentration of said cardioplegic solution between about 50-300 umol; maintaining said concentration of metabolizable substrate in said cardioplegic solution between about 400-1000 mg %; and maintaining said osmolarity of said cardioplegic solution between about 400-500 mOsmol.
Claim 9
Dependent Claim
82 words
In a method for treating human hearts with an amino acid enriched cardioplegic solution to prevent or reverse heart muscle damage due to ischemia, said solution having a calcium ion concentration, a metabolizable substrate concentration and an osmolarity, wherein the improvement comprises: maintaining said calcium ion concentration of said cardioplegic solution between about 50-300 umol; maintaining said concentration of metabolizable substrate in said cardioplegic solution between about 400-1000 mg %; and maintaining said osmolarity of said cardioplegic solution between about 400-500 mOsmol.
Claim 10
Dependent Claim
22 words
An improved method according to claim 7 wherein said metabolizable substrate is selected from the group consisting of glucose, succinate and pyruvate.
Claim 11
Dependent Claim
28 words
An improved method according to claim 7 wherein said solution includes a carrier selected from the group consisting of blood, stroma free hemaglobin, oxygenated plasma, crystalloids and fluorocarbons.
Claim 12
Dependent Claim
13 words
An improved cardioplegic solution according to claim 9 wherein said carrier is blood.
Claim 13
Dependent Claim
18 words
An improved method according to claim 8 wherein said solution includes 10-30 mmol aspartate and 10-30 mmol glutamate.
Claim 14
Dependent Claim
13 words
An improved method according to claim 10 wherein said metabolizable substrate is glucose.
Claim 15
Dependent Claim
78 words
A composition of matter for introduction into human hearts to prevent or reverse heart muscle damage due to ischemia, said composition of matter comprising: an aqueous solution which is adapted to be diluted with a cardioplegic compatible diluent to provide a cardioplegic solution having between about 50-300 umol calcium ion, 20-60 mmol amino acid selected from the group consisting of glutamate and aspartate, 400-1000 mg % of a metabolizable substrate and an osmolarity of between about 400-500 mOsmol.
Claim 16
Dependent Claim
78 words
A composition of matter for introduction into human hearts to prevent or reverse heart muscle damage due to ischemia, said composition of matter comprising: an aqueous solution which is adapted to be diluted with a cardioplegic compatible diluent to provide a cardioplegic solution having between about 50-300 umol calcium ion, 20-60 mmol amino acid selected from the group consisting of glutamate and aspartate, 400-1000 mg % of a metabolizable substrate and an osmolarity of between about 400-500 mOsmol.
Claim 17
Dependent Claim
35 words
A composition according to claim 13 wherein said metabolizable substrate is selected from the group consisting of glucose, fructose, a salt of malic acid, a salt of succinic acid and a salt of pyruvic acid.
Claim 18
Dependent Claim
12 words
A composition according to claim 14 wherein said metabolizable substrate is glucose.
Claim 19
Dependent Claim
33 words
A composition according to claim 13 wherein said aqueous solution is adapted to be diluted in a ratio of approximately 1 to 4 with said cardioplegic compatible diluent to provide said cardioplegic solution.
Claim 20
Dependent Claim
13 words
A composition according to claim 13 wherein said cardioplegic compatible diluent is blood.
Claim 21
Dependent Claim
18 words
An improved cardioplegic solution according to claim 1 wherein the pH of said solution is between about 7.5-7.7.
References Cited (Backward Citations)
US4249923A
Cited
US4254081A
Cited
US4416280A
Cited
US4314550A
Cited
US4415556A
Cited
US4427009A
Cited
US4433971A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-28 | 1994-07-30 | 1995-01-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-28 | 1998-07-30 | 1999-01-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-28 | 2002-07-30 | 2003-01-29 | $7700.00 | Window Closed / Lapsed |